Join our daily newsletter At The Bell to receive exclusive market insights
- Biotech company Next Science (NXS) receives licensing approval for XPERIENCE to be sold in Canada, effective immediately
- NXS will build a sales agent distribution network and will begin a major randomised control study which will compare XPERIENCE against current standard of care
- XPERIENCE is designed for use in open surgical procedures where the residual solution remains in the surgical site after closure
- It is used to defend against pathogens for several hours by rinsing away debris and micro-organisms, helping prevent surgical site and post-operative infections
- Next Science is up 1.68 per cent on the market with shares trading at 91 cents at 12:57 pm AEST
Biotech company Next Science (NXS) has received licensing approval for XPERIENCE to be sold in Canada, effective immediately.
XPERIENCE was launched in the US in April 2021 and applied for licensing in Canada in May 2021.
Next Science will build a sales agent distribution network and will begin a major randomised control study which will compare XPERIENCE against current standard of care.
The study will be based out of the University of Ottawa.
XPERIENCE is designed for use in open surgical procedures where the residual solution remains in the surgical site after closure.
It is used to defend against pathogens for several hours by rinsing away debris and micro-organisms, giving surgeons a simple adjunct to help prevent surgical site and post-operative infections.
“We are thrilled to see this licence come through and can now move to both commercial and clinical research activity in Canada. We look forward to the differences we can show in such a well-documented health system,” Managing Director Judith Mitchell commented.
Next Science was up 1.68 per cent on the market with shares trading at 91 cents at 12:57 pm AEST.
